INT98788

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 2001
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 11
Total Number 11
Disease Relevance 3.65
Pain Relevance 1.64

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (EPHB1) signal transduction (EPHB1) plasma membrane (EPHB1)
cytoplasm (EPHB1)
Anatomy Link Frequency
autonomic 1
EPHB1 (Homo sapiens)
Pain Link Frequency Relevance Heat
antidepressant 12 98.70 Very High Very High Very High
intrathecal 1 98.56 Very High Very High Very High
Analgesic 2 98.08 Very High Very High Very High
tricyclic antidepressant 6 96.56 Very High Very High Very High
Serotonin 5 95.00 High High
Dopamine 1 94.44 High High
Neurotransmitter 7 92.56 High High
monoamine 2 91.88 High High
antagonist 18 90.08 High High
aspirin 4 88.56 High High
Disease Link Frequency Relevance Heat
Attention Deficit Hyperactivity Disorder 71 99.14 Very High Very High Very High
Heart Rate Under Development 160 98.84 Very High Very High Very High
Frailty 5 94.96 High High
Postural Orthostatic Tachycardia Syndrome 340 93.12 High High
Syndrome 15 89.84 High High
Chronic Disease 4 84.08 Quite High
Aging 1 78.64 Quite High
Neuropathic Pain 32 77.96 Quite High
Targeted Disruption 1 77.24 Quite High
Increased Venous Pressure Under Development 24 72.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
DISCUSSION: In the present study we describe key features of in vitro assay methodology that can influence the apparent pharmacological profiles of standard SERT and/or NET inhibitors.
Negative_regulation (inhibitors) of NET
1) Confidence 0.37 Published 2010 Journal J Pharmacol Toxicol Methods Section Body Doc Link 20036748 Disease Relevance 0 Pain Relevance 0
Definition of NET
Negative_regulation (Definition) of NET
2) Confidence 0.35 Published 2009 Journal Trials Section Body Doc Link PMC2646715 Disease Relevance 0.24 Pain Relevance 0
The conopeptide chi-MrIA is a noncompetitive and highly selective inhibitor of the NE transporter (NET) and is being developed as a novel intrathecal analgesic.
Negative_regulation (inhibitor) of NET associated with analgesic and intrathecal
3) Confidence 0.24 Published 2007 Journal J. Biol. Chem. Section Abstract Doc Link 17428804 Disease Relevance 0 Pain Relevance 0.59
This perspective reviews recent human and mouse studies that suggest how peripheral autonomic phenotypes, linked to genetic disruption of NET and SERT function, can aid in the phenotypic segregation needed for advanced theories of biogenic amine dysfunction and pharmacogenetics.
Negative_regulation (disruption) of NET in autonomic
4) Confidence 0.19 Published 2001 Journal J. Neurosci. Section Abstract Doc Link 11606618 Disease Relevance 0.06 Pain Relevance 0.17
Many antidepressant and attention deficit medications work at least in part through inhibition of NET.
Negative_regulation (inhibition) of NET associated with antidepressant and attention deficit hyperactivity disorder
5) Confidence 0.08 Published 2006 Journal Indian Pacing and Electrophysiology Journal Section Body Doc Link PMC1501099 Disease Relevance 0.81 Pain Relevance 0.20
Potentially contributory medications (especially vasodilators, diuretics, and drugs that inhibit NET) should be withdrawn.
Negative_regulation (inhibit) of NET
6) Confidence 0.08 Published 2006 Journal Indian Pacing and Electrophysiology Journal Section Body Doc Link PMC1501099 Disease Relevance 0.68 Pain Relevance 0.28
Both we [31] and others [32] have found that pharmacological NET inhibition can recreate an orthostatic tachycardia phenotype in susceptible healthy volunteer subjects.
Negative_regulation (inhibition) of NET associated with heart rate under development
7) Confidence 0.06 Published 2006 Journal Indian Pacing and Electrophysiology Journal Section Body Doc Link PMC1501099 Disease Relevance 0.83 Pain Relevance 0.19
Although functional NET mutations might be infrequent, pharmacological NET inhibition is very common.
Negative_regulation (inhibition) of NET
8) Confidence 0.06 Published 2006 Journal Indian Pacing and Electrophysiology Journal Section Body Doc Link PMC1501099 Disease Relevance 0.81 Pain Relevance 0.20
Conversely when the amount of nitrogen excreted exceeds the amount of nitrogen consumed, the individual has entered into negative nitrogen balance, and is assumed to be in a state of net bodily protein loss (catabolic state) [9].
Negative_regulation (loss) of net
9) Confidence 0.02 Published 2006 Journal J Int Soc Sports Nutr Section Body Doc Link PMC2129150 Disease Relevance 0.06 Pain Relevance 0
in the media measured by ELISA in HEK-APPNFEV were also unexpectedly reduced by 24% in HEK-APPNEFV overexpressing OSBP1 (data not shown), suggesting again that OSBP1 overexpression impacts the non-amyloidogenic processing of APP in a more complex manner.


Negative_regulation (reduced) of HEK-APPNEFV
10) Confidence 0.01 Published 2008 Journal Mol Neurodegener Section Body Doc Link PMC2323375 Disease Relevance 0 Pain Relevance 0
Figure 9 gives a breakdown of the 131 EpiphaNet searches conducted during the ten sessions.
Negative_regulation (breakdown) of EpiphaNet
11) Confidence 0.01 Published 2010 Journal J Biomed Discov Collab Section Body Doc Link PMC2990276 Disease Relevance 0.16 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox